Helping people in need !!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here they tell the amount of the BARDA deal. Total $9.2 mm.
This is the initial procurement. MEANS there will be more ordering some time in the future. THEIR PRODUCTS ARE GOOD. Seems BARDA agrees. This is a small company with a bright future !!
https://ir.avitamedical.com/news-releases/news-release-details/barda-initiate-procurement-recellr-system-emergency-response
Not WRONG read it again I know it mentions emergency use only check this out From the cellculturedish June 4 interview...clear evidence of MS efficacy in donated transplant lung function (ex spleen/harvested transplant lungs)...
"Athersys was also doing work with several of the leading transplant centers in the United States at this time. Investigators at these centers came to Athersys with a problem that is widespread in the field of lung transplantation. About seventy-five percent of lungs that are isolated from organ donors become highly inflamed and start to essentially go bad before the transplant procedure can be conducted. Once the lungs are harvested from the donor they are either put on ice or stored for the subsequent transportation procedure. The pulmonary tissue begins to experience inflammation, which causes the lungs to become compromised, (very frequently within just a few hours). The lungs become highly inflamed and filled with fluid, thus rendering them unusable. Doctors can’t transplant inflamed lungs into a patient needing a transplant because essentially they would have ARDS immediately. To see if Multistem could make a difference, investigators proposed taking lungs where there was severe inflammation and infusing one side with Multistem compared to the other side to be used as control. Since Athersys had seen restoration of pulmonary function and reduced inflammatory mediated cascade pathways in animal models, they had the basis for a study on human lungs that were isolated from donors. There was a dramatic impact when one side of the lungs was perfused with Multistem. It actually caused the pulmonary function to return to normal range and dramatically reduced the inflammatory mediated damage. The transplant specialists immediately suggested a study taking human lungs from donors and perfusing them with Multistem as a way to prepare these lungs for transplant. Ultimately though this represents a limited number of patients in the United States, somewhere around fifteen hundred to two thousand patients per year. With those numbers sufficient clinical trial enrollment would be difficult.
So Athersys decided to look at ARDS because it is the same clinical process and there are more patients with this affliction per year. Athersys ran a clinical trial at about a dozen leading pulmonary critical care centers in the United States and the UK. Dr. Van Bokkelen shared that the highlights from the one-year study follow up were recently announced demonstrating that Multistem helped patients in the short term by improving clinical metrics and odds of survival. In addition, Multistem dramatically improved quality of life outcomes for many of these patients, particularly among the most severely ill.
Another indication that Dr. Van Bokkelen described was using Multistem to treat ischemic stroke patients, another huge area of unmet medical need. He explained that after ischemic stroke, there is a very tight time window for patients to get to the hospital and then undergo treatment. Furthermore there are limited treatment options currently available. Athersys conducted a phase two clinical trial using Multistem for treatment of ischemic stroke. The study showed that Multistem could effectively help patients for up to thirty-six hours after they had suffered an ischemic stroke.
For both ARDS and for ischemic stroke Athersys has received fast track designation from the FDA. They are now well into a Phase III study for stroke patients with the belief that for both ARDS and for stroke, they can improve clinical care for patients that in many instances would otherwise have no good therapeutic options. Dr. Van Bokkelen, closed by saying, that providing therapeutic options where none previously existed was exactly why Athersys was founded twenty-five years ago and that this is the type of impact that they are really committed to making .. GOOD LUCK LONG
Catch up SHIP is NOT sinking alllllllllll Aboard !!!
https://www.seanergymaritime.com/en/
NIH just shot down Mesenchymal Stem cells for covid 19 treatments. MULTISTEM only game in town now. The MultiStem clinical product is developed from a special ### of stem cells called Multipotent Progenitor Cells, or MAPC. These cells are distinct from mesenchymal stem cells (MSCs) and other cell types. They are obtained from healthy bone marrow and may be expanded outside the human body using proprietary manufacturing processes. These cells may be administered without tissue matching or immune suppression, results show they are capable of promoting healing and tissue repair in multiple ways. GOOD LUCK LONGS
Let's not forget the products T2 for sepsis, Sepsis ranges from less to more severe. As sepsis worsens, blood flow to vital organs, such as your brain / heart and kidneys becomes impaired. Sepsis can also cause blood clots to form in your organs and in your arms / legs / fingers and toes leading to varying degrees of organ failure. This is why early detection at the time of Covid 19 is also important. It will save lives bottom line.
Now that options have expired, M'M might let this one go over $2 just a thought !!
This happen last week etc Don't forget Athx partner Healios get’s a Grant to work on ARDS by NIBIOHN Notification of grant items for product testing and research grants for orphan drug, orphan medical device, orphan regenerative medicine Also there's another agreement with Regeneron is the first of a number of Operation Warp Speed awards to support potential therapeutics all the way through to manufacturing, allowing faster distribution if trials are successful,” said HHS Secretary Alex Azar. “More good news about COVID-19 therapeutics is constantly emerging, and President Trump’s commitment to supporting lifesaving therapeutics will help deliver these products to American patients without a day’s delay.” MACOVIA 60 data in hand, federal government is desperate need of MULTISTEM. We have to stop the death count. Upside $20.00, blue sky $37.00 downside .50 cents. Shorts !
Less
listened to Dr. Ivor Macleod Dr. GVB & Dr. Macleod are creating the next AMGN right in front of your eyes. Believe and you will be set free of any financial worries! LOOK IT UP AND LISTEN ITS THERE FOR UUUUUUUUUUUUUUUUUUUUUUUUUU
A little off topic but related. For some of the Investors that are here for the science of stem cell I have a friend going through a stem cell experience with my dog. Yesterday he received stem cell therapy. He's an 8 year old German Shepherd with Degenerative Myelopathy. In humans you can compare it to ALS. The protective sheathing around the spinal cord begins to deteriorate and the loss of motor control and feeling usually starts in the rear legs and progresses. Animals Stem cells have been used with good success for arthritic and damaged joints. However it is not approved for Degenerative Myelopathy except for compasionate use. working with the Veternarian and the Bio-Vet Pharma we all agreed on a protocol. Time will tell. A synopsis of what has transpired starts with acquiring the stem cells. The vet surgically removed fatty tissue from my dog then with the Bio-Vet Pharma equipment starts the process of cultivating stem cells to be injected or IV drip into the dog. In addition to the stem cells he was also given with platelet-rich plasma to promote the process. In my case my dog got stem cell injections in two rear joints (arthritic) and an IV drip for the Degenerative Myelopathy. The stem cells that were not used are now at the Bio-Vet's cryo-bank (frozen) for future injections. His prognosis is not great because of the severity of his Degenerative Myelopathy but if it slows the progression that is a huge success. In 30 and then 60 days he'll have a another dose of stem cells again. All this was done in 1 day. If the therapy helps I would anticipate improvement or a slowing of the progression within 4 months. Anyone that has a German shepherd or many of the large breeds know that medically they can be challenging. I'll try to update the dogs status as time goes by.
ATHX Insane volume after hours is a FACT, in the money $3.00 options will be converted to shares plus HTB(Hard To Borrow) for both my Ameritrade and Schwab accounts. Double whammy for shorts and a triple threat if binary news hits the wires. ATHX could open over double digits if we get BARDA or other government collaboration/funding. Pandemic is going to level I never thought possible, we need MULTISTEM approval now !
This was a GOOD week ALWAYS remember TTOO is not just COVID testing. It also innovate testing for various threats.
Not everyone knows about ATHX Yet. Gil has a tight lid on everything and when he's ready to share ATHX will open allllllll gates !! This may not explode in one day, but definitely it WILL be a winner in the long run .. GOOD LUCK LONGS
Absolutely
Capesizes have settled above $30,000 per day this month with an increasing amount of analysts suggesting the good times are here to stay for the rest of 2020.
Cleaves Securities’s latest 309-page quarterly report has dry bulk as its top sector pick, citing very strong Chinese demand for dry bulk as the economy is normalising and authorities are adding stimuli.
“Chinese steel production reached a new all-time-high in May, and inventories of steel and iron ore have fallen rapidly. With Brazil finally ramping up iron ore exports from early June, earnings have surged. We believe 2H20E could be very strong, and see consecutive annual gains at least until 2023E,” Cleaves stated.
The dark days of the first five months of the year have been replaced with renewed confidence among cape owners, brokers Intermodal stated in its latest weekly report, describing the “enhanced psychology” providing the market with the “steam” needed to move further ahead.
“Looking at owner’s ideas, it is clear that they are more confident to exert resistance T/C average rates at higher levels day by day,” Intermodal suggested.
Breakwave Advisors are similarly bullish on short-term prospects, albeit with the caveat of increased volatility.
“The near-term outlook still looks promising, yet care is needed given the significant move in spot rates. We expect the second half of 2020 to see Capesize rates trading in a range of 15,000-45,000. This is wide, but not unheard of. We also expect the 2H average Capesize rate to exceed last years’ level (~26,000/day), which means freight futures for the second half are still cheap, in our view (currently ~22,000/day),” the American company predicted this week.
Braemar ACM noted the growing cape congestion at Chinese ports in recent days on bad weather and increased import volumes.The volume of capesize tonnage waiting at Chinese ports jumped to over 16m dwt last week, the highest level in over two years according to AIS data from Refinitiv.
Over July so far Braemar ACM has recorded an average of 15.2m dwt of capacity waiting, 41% higher than average congestion during this period over 2015-19 and 33% higher than last month’s average.
This is adding to the ongoing squeeze to supply of ships in the Pacific.
“Heavy seasonal rains are reportedly slowing the rate that incoming vessels can be discharged, but the queues are also in part down to China’s enormous purchases of iron ore over the past few weeks, some of which would otherwise be heading to countries which have cut back their imports, such as Japan and South Korea,” Braemar ACM noted in a dry bulk update.
"In analyzing blood, tissue, immune cells and other samples from the patients, the researchers came upon what they believe is a signature for people with severe infections—a combination of an interferon response deficiency and exacerbated inflammation. They suggest the signature may represent a hallmark for severely ill COVID-19 patients. The researchers suggest their findings could lead to therapies that boost interferon response to an infection while also reducing inflammation."
https://medicalxpress.com/news/2020-07-hallmark-severe-covid-patients.html
What’s teased as “The #1 Stock to Profit from the Big Biotech Boom?” Checking out the teaser pitch from Biotech Millionaire
By Travis Johnson, Stock Gumshoe, July 15, 2020
Irregulars Quick Take
Paid members get a quick summary of the stocks teased and our thoughts here. Join as a Stock Gumshoe Irregular today (already a member? Log in)
Today we’re headed into the wild and woolly world of biotech once again, sniffing out the secret stock from a teaser pitch for Biotech Millionaire, edited by Chris Wood and Jake Weber over at Mauldin Economics ($1,795/yr, includes their Healthy Returns letter… and unlike most higher-cost letters these days, they actually offer a 30-day refund period, so we should say “good for them” on that front).
The ad begins with a spiel about the “Hawking Factor” — which, to summarize, is basically the idea that a treatment that can offer reversal of a disease… some sort of regenerative factor… is far more valuable than a drug that can just stop its progression. There are drugs for ALS, for example, but none that reverse it, and therefore Stephen Hawking was treated for his slow deterioration and was able to live for 50 years with ALS, but a revolutionary treatment would have been one that actually reversed the disease. Here’s how they put it:
“A treatment that doesn’t just save the life of the patient but could completely transform it by reversing the symptoms.
“Reversing disease is the latest example of revolutionizing science, which Hawking was all about.”
So that’s the idea, which probably means we’re dealing with something in regenerative medicine, either stem cells or something similar. What, then, is this secret biotech that they dangle before us as we fumble for our credit cards? Apparently they’re also a bit topical, and they’re doing something that might help COVID-19 patients… this is how they sum it up on the order form:
“This company is testing a groundbreaking treatment for stroke and ARDS, the leading cause of death in COVID-19 patients… for projected gains of up to 1,270% in the next 12–18 months.”
The primary focus of the company seems to be on treatment for strokes, here’s a bit about that from the ad: it aids doctors in the fight against one of the world’s largest killers: stroke.
“According to the CDC, acute ischemic strokes strike almost 800,000 Americans per year and kill 140,000.
Are you getting our free Daily Update. There are about 15 million cases of stroke worldwide every year.
“Stroke is the #1 cause of disability and the #3 cause of death worldwide.”
And we’re told that although there are very good treatments for strokes like this, they have to be administered within hours of the event… which means that people who don’t immediately get to a hospital are out of luck. This new treatment can be effective on people for much longer, which is why the market for the drug could be dramatically larger… more from the ad…
“It’s not a drug in the traditional sense. It’s a stem cell therapy….
“It can effectively treat patients up to 36 hours after they’ve suffered a stroke which would make 90–95% of stroke patients eligible for treatment. This is a HUGE milestone for modern medicine.”
OK, so there’s our confirmation of the “stem cell” idea. What else do we learn about this secret stock? More clues from the pitch…
“We’re looking at late-stage clinical trials that are already well underway. But this cell therapy has even more exciting applications. Aside from stroke, one of the main killers of people worldwide it can treat the leading cause of death from COVID-19: Acute respiratory distress syndrome (ARDS).
“The tiny company I’ve vetted is the only one in the world that has shown promise in the treatment of ARDS.”
And that COVID-19 stuff sounds impressive, particularly given how brutal an extended time on a ventilator can be for your body…
“Most vaccines and antiviral treatments that are in the works to treat COVID-19 are specific to the virus.
“This therapy is not.
“That means we could use it to treat any future viral outbreak that causes ARDS—no matter what the virus is.
“Also: This amazing ‘Hawking Factor’ therapy can not only reduce inflammation in the lung it can regenerate tissue.”
I guess it makes sense that the treatment is not COVID-specific, since they’re talking about using the same drug for stroke patients.
Other clues?
They’ve been granted fast-track status by the FDA, presumably for the COVID/ARDS treatment.
And it’s a universal stem cell treatment, not a personalized one — so you don’t have to have a donor match to you, or create pluripotent stem cells from your own body, it’s something that is standardized and can be stored by a pharmacy… the ad says it can be “administered to the patient in less than an hour,” and if they’re mentioning that time to treatment
www.newsdriveninvestor.com/potential-cobalt-demand-undervalued/
TTOO announced the completion of validation of its COVID-19 molecular diagnostic test, the T2SARS-CoV-2 Panel. However, this business could possibly meet the demand of electric vehicles for cobalt. Learn more:
www.newsdriveninvestor.com/potential-cobalt-demand-undervalued/
bb.. This is the same stem cells that they sold to Helios, as an extra product to deal with eyes-mac degeneration.. It does have merit, as there will be a revenue stream - royalties. Something like this might be 8-12% of sales. Plus a license fee to
sell the product in US, or wherever.
Just for allllllllllll you so called Moderates .. I've NEVER ever ONCE ATTACKED you "ONLY THE BEST CEO OF ALLLLLL TIMES" That took advantage of his LOYAL shareholders !!!! I can still hear the guys describing how YOUR SO CALLED CEO was CRYING like a LITTLE baby after a few slaps .. YEAH that's right MY GROUP was looking OUT for everyone's including yours !!! Yeah Waaaa waaaa waaaa
So be careful what you say because you have NOTHING that YOU bring to this so CALLED Company .. Keep on chasing your tails you might catch up with it some day .. LOL LOL LOL LOL
I'm NOT crying FACTS are FACTS .. Made back WELL over 7 figures in the past few months ..The good thing, I'll get to keep a lot $$$ for my pass loses with this so Co. YOU keep on defending or is it that your one of many Moderator's … Yeah amazing how WELL this SO CALLED SCAM CO. has TREATED alllllllll their loyal shareholders .. I forget do you still have THE BEST CEO OF ALLLLLLLLL TIMES .. LOL
Moderators: Talking to each other .. LOL WHAT ABOUT THE BEST CROOKED CEO OF ALLLLLLLLL TIMES .. SHUT THE LIGHTS OFFS !!!!!
I'll end it here take a look and I wish everyone the BEST ..
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=acrgf&insttype=&freq=&show=
https://www.marketwatch.com/investing/stock/ACRGF/profile
I'll end it hear take a look and I wish everyone the BEST ..
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=acrgf&insttype=&freq=&show=
https://www.marketwatch.com/investing/stock/ACRGF/profile
Sorry, I can go on and on .. With NO re-turn calls for months hit a NEW LOW and time to move on ..
https://www.marketwatch.com/investing/stock/APHA/profile
Compare this Co. and the whole industry to MCOA …
MCOA will NOT be able to survive !!
https://www.marketwatch.com/investing/stock/KSHB/profile
Another Co. to watch and compare …
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=hexo&insttype=&freq=1&show=True&time=8
Here's another Co. to compare to MCOA .. We tried calling many times with NO response … It's been going TO LONG with NO re-turn call .. We have over 500K invested in this SCAM which this week we have cut our loses and moving on ..
https://www.marketwatch.com/investing/stock/TLRY/profile
Here's a Co. with plenty of sales which it seems MCOA is pretty much done .. HATE TO SAY !!https://www.marketwatch.com/investing/stock/AKRX/profile
Yes its a scam NO DIFFERENT than the SCAMS CO'S you follow it's like buying a LOTTERY TICKET with HOPE and using your OWN MONEY .. IF you don't BELIEVE that I WILL ALSO SELL YOU SOME PILLS … LOL
Agree, I should have done it LONG ago .. Some people will always have SOMETHING to SAY and NOTHING to CONTRIBUTE.
Ignore This Member "UPGOOD" BYE BYE having my post removed says ENOUGH !!!!!!!
Good read … Apr 02, 2020 (Stock Market Press via COMTEX) -- More states, such as Florida, issued coronavirus related stay-at-home orders yesterday (April 1, 2020). CBD is not a cure for COVID-19, but it offers relief from anxiety and stress by people who fear they, family or friends may contract it. As a result, we have seen CBD products show staying power in sales during the crisis -- selling online, in dispensaries and other licensed retailers deemed essential businesses by state and local authorities.
The global impact of the coronavirus has intensified coverage of companies that market CBD and other health-related products.
CBD Sales Spiked Prior To Shelter-In-Place Orders, But Its Staying Power Now Is Not As A Coronavirus Cure But As A Reducer Of Anxiety And Stress
CBD is not a cure or protocol for medically treating the coronavirus but its properties address key elements. It is known to offer anti-viral, anti-inflammatory and anti-bacterial properties. It also acts as an effective treatment for nausea and vomiting, which can be induced by the coronavirus in humans. Just as important, CBD can be a relaxant for anxiety and stress of home-bound people fearful of catching the virus. CBD sales spiked prior to shelter-in-place orders, but its staying power now is not as a coronavirus cure but as a reducer of anxiety and stress.
Nationwide online sales of CBD jumped 230% prior to the coronavirus quarantines and in California orders hit a record peak after Gov. Gavin Newsom issued his shelter-in-place order for the state, the Wall Street Journal reported, based on data from website Weedmaps. As more states mandate stay-at-home orders with only essential travel permitted (visits to groceries and pharmacies), several states have ruled that CBD dispensaries and licensing shops are essential and can remain open during the crisis. CBD sales spiked prior to shelter-in-place orders, but its staying power now is not as a coronavirus cure but as a reducer of anxiety and stress.
As a result, CBD is playing an important role in calming the nerves of shut-ins. The conclusion